Clinical Trials
7 trialsNCT06868433 2026-03-04
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Emory University
Phase 1 Recruiting
NCT03589339 2025-10-24
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
Phase 1 Active not recruiting
NCT02586207 2025-10-07
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
Phase 1 Completed
NCT04301011 2025-04-23
RAPTOR
Turnstone Biologics, Corp.
Phase 1 Terminated
NCT04576091 2024-12-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03809624 2024-10-23
PDL1x41BB
Inhibrx Biosciences, Inc
Phase 1 Terminated
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed